Qlaris Bio, Inc.

Quick facts

Phase 2 pipeline

• QLS-101
• QLS-101 ophthalmic solution, 2.0 %
• QLS-101ophthalmic solution 1%
• QLS-101ophthalmic solution 2%
• QLS-111, 0.015%
• QLS-111, 0.030%
• QLS-111, 0.075%

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Qlaris Bio, Inc. portfolio CI brief
• Qlaris Bio, Inc. pipeline updates RSS